Navigation Links
Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
Date:11/28/2012

PRINCETON, N.J., Nov. 28, 2012 /PRNewswire/ -- On November 9, 2012, Ranbaxy Inc. initiated a voluntary recall of 41 affected lots of Atorvastatin Calcium Tablets (10 mg, 20 mg and 40 mg) which is a solid oral dosage form, to the retail level. The Company is taking this voluntary action as a precautionary measure due to the fact that we cannot exclude the possibility that the affected lots may contain very small glass particles resembling a fine grain of sand (less than 1 mm in size). This information is available in Ranbaxy's website at www.ranbaxyusa.com. The recall does not affect or relate to the 80 mg dosage strength of Atorvastatin Calcium Tablets.

The probability of an adverse event due to consumption of this product is unlikely but cannot be ruled out.  Because of the size of the particles which may be present in the affected lots it is unlikely to cause a significant safety concern. However, the possibility of adverse experiences arising primarily due to physical irritation cannot be ruled out. As of this date, Ranbaxy has not received any reports of adverse events related to this recall.

The product is used to lower blood cholesterol and is packaged in plastic bottles, as 90 and 500 tablets per bottle. The affected lots of Atorvastatin Calcium Tablets and their respective NDC code, expiration date information are listed below. The product is a white colored tablet and can be identified by the imprint RX12 on 10 mg tablets, RX828 on 20 mg tablets and RX829 on 40 mg tablets.  The product was distributed in the USA to wholesalers and retailers.

Ranbaxy has notified its distributors and retailers by e-mail/ FedEx and has arranged for return of the affected lots.  Distributors/retailers have stopped further distribution of the affected lots and are in the process of returning any affected product to Ranbaxy.

Consumers with questions regarding this recall can con
'/>"/>

SOURCE Ranbaxy Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
2. Ranbaxy Commends New IMS Study Which Credits Generic Prescription Drugs With $1 Trillion Savings In U.S. Health Care Costs Over Past 10 Years
3. Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA
4. Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Companys Phase III FDA Sickle Cell Treatment Trials
5. Zi Xiu Tang Success, LLC Issues Voluntary Nationwide Recall of Classic Zi Xiu Tang Bee Pollen Capsules and Ultimate Formula Capsules due to Undeclared Sibutramine
6. CORRECTION: Star Scientific Issues Statement Correcting the Underreporting of the "Flint" CRP Human Study Results
7. Qualitest Issues Voluntary, Nationwide Recall for One Lot of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
8. Sun Pharmaceutical Industries, Inc. Issues Nationwide Voluntary Recall of One Lot of Nimodipine Capsules due to Crystallization of the Fill Material
9. Health Outcome Liaisons Improve Decision Making for Pharmaceutical Industry Challenged by Reform and Compliance Issues
10. Joint Commission Issues Sentinel Event Alert on Opioid-Induced Respiratory Depression
11. National Sleep Expert Issues Warning about Popping Pills to Replace Sleep
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Ill. , July 22, 2014  UL ... announced that the U.S. Food and Drug Administration ... as consensus standards for medical devices incorporating lithium ... 2054 - Standard for Household and Commercial Batteries, ... (Cells). Consensus standards are standards ...
(Date:7/22/2014)... N.J. , July 22, 2014  Vernalis plc ... achievement of proof-of-concept (POC) for CCP-08, the third ... prescription cough cold collaboration. Under this collaboration, POC ... a successful human pilot comparative study against an ... achieving POC, Vernalis will make a milestone payment ...
(Date:7/22/2014)... SAN MARCOS, Texas , July 22, 2014 Quantum ... Martin and Mr. John Heaton to the Board ... chaired by Dr. Ghassan Jabbour , QMC Chief Science Officer ... Dr. Michael Wong of Rice University and Mr. ... Japan . " Quantum Materials ...
Breaking Medicine Technology:Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... Bowl champion coach, Fox NFL Sunday host and ... ExtenZe, the male enhancement brand, he has good-naturedly taken a ... national television. Now, in this next flight of ... fun, laughing about being put on the spot and made ...
... AMGN ) today announced that results from ... be presented at the 35th European Society for Medical ... "Cancer is a complex disease which ... pathways to develop novel therapies to treat cancer and ...
Cached Medicine Technology:Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His 'Notoriety' in New ExtenZe Spots from Inter/Media Advertising 2Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His 'Notoriety' in New ExtenZe Spots from Inter/Media Advertising 3Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 2Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 3Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 4Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 5Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 6Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 7Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 8Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 9Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 10Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 11Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 12Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 13Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 14Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 15Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 16
(Date:7/22/2014)... SIMpalm, a leading Mobile App Development ... Payment System. Forte Mobile Payment app allows merchants to ... and iPad. The app was originally launched in ... This update was for iOS 7.0 compatibility and iPhone ... and is available to download on the iPhone app ...
(Date:7/22/2014)... cholesterol treatment and cardiovascular risk assessment state that men ... atherosclerotic cardiovascular disease or of having a heart attack ... profile (based on age, smoking history, and cholesterol and ... when and how aggressively to treat high cholesterol are ... Health , a peer-reviewed publication from Mary Ann Liebert, ...
(Date:7/22/2014)... TX (PRWEB) July 22, 2014 The ... Program and third annual Institute Scholar Program. These offerings ... of the patient experience in healthcare and the need ... , The grant and scholar programs are ... , Value of focusing on the patient ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... park is the heart of a community. That’s ... made a recent investment in outdoor recreation and fun ... equipment from American Parks Company™. , The community of ... a 475-unit community that was established in the 1970s. ... tropical paradise with lush shade trees, green-edged walking and ...
Breaking Medicine News(10 mins):Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... with The Bakersfield based Comprehensive Blood and Cancer center (CBCC), ... an other six months the CBCC of US is to ... Kuruvilla the CEO of Apollo Hospital said that, "It will ... have within the hospital premises a separate unit that will ...
... A new ultra light hand, called the 'Southampton Remedi-Hand' has been ... hand better than any currently available. // ,The human hand ... movements and actions. The artificially developed hand is dependent on 6 ... way so as to enable independent movement of all the five ...
... that their neighborhoods are safe then their preschool children ... points out that this does not mean that these ... comparison with their counterparts in unsafe neighborhoods. ,Drawing ... researchers reported these findings in the September issue of ...
... acid as found to reduce the rate of birth defects. ... found that more than one third of birth defects are ... Spina bifida and anencephaly, known as neural-tube defects, arise when ... close during the first weeks of pregnancy. The defect causes ...
... emergency room with cervical spinal injury may have more damage ... published in the Annals of Emergency Medicine, say that CT ... over and above the normal X-rays.// ,The study indicates ... additional spinal damage not visible on regular x-rays. In fact, ...
... announcement the Health Minister of West Bengal Mr.Surya Kanta Mishra ... and the numbers of cases detected were increasing in ... other than dengue, malaria, typhoid, viral fever and encephalitis were ... was also reported in N.Delhi last week in India. Dengue ...
Cached Medicine News:Health News:New ultralight hand with better functionality and flexibility developed 2Health News:Safe Neighborhood Means Less TV For Preschool Children 2Health News:Folic acid enriched grain reduces birth defects 2
BD Vacutainer® Fluoride Tubes - Glass...
BD Vacutainer® Specialty Tubes - Trace Element - Glass...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: